CAR T Cells and T-Cell Therapies for Cancer

CAR T-cell therapy for cancer is explored, focusing on its mechanisms, effectiveness, and challenges. Jennifer Brudno, Associate Research Physician at the National Cancer Institute, explains that CAR T-cells are genetically engineered T-cells designed to target and kill malignant cells expressing specific antigens. The therapy has shown significant success in B-cell malignancies like lymphoma and acute lymphoblastic leukemia, with some patients achieving long-term remission even after chemotherapy failure. The process involves collecting the patient's T-cells, modifying them ex vivo, and infusing them back into the patient after a conditioning chemotherapy. Despite high response rates, challenges remain, including logistical issues like wait times for cell manufacturing, the therapy's high cost, and potential adverse effects such as cytokine release syndrome and neurological toxicities.